Slides
Page 1
NuvectisPharma , Inc. Nuvectis Pharma , Inc. ( NASDAQ : NVCT ) Precision Medicine for the Treatment of Complement Related Diseases and Cancer August 2026
Page 2
NuvectisPharma, Inc. Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the U.S. federal securities laws, which statements are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this presentation are forward-looking statements. Forward- looking statements contained herein may be identified by the use of words such as "anticipate” , "believe” , "contemplate” , "could” , "estimate” , "expect” , "intend” , "seek” , "may” , "might” , "plan” , "potential” , "predict” , "project” , "target” , "aim” , "should” , "will” , "would” , or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding future events, including statements about the use of proceeds from the public offering and the approvability and market potential of our pipeline products. Forward looking statements are based on Nuvectis’ current expectations, estimates, and projections and past interpretations of data and information available, including preclinical and clinical safety, pharmacokinetics, pharmacodynamics, and efficacy data generated to date for its pipeline products NXP100, NXP200, and NXP900, and estimates and projections regarding the approvability and commercial potential of these pipeline products, as well as Nuvectis’ financial condition. The outcome of the events described in these forward-looking statements are subject to inherent uncertainties, risks, assumptions, market and other conditions, and other factors that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are subject to market and other conditions and described more fully in the section titled "Risk Factors" in our second quarter 2026 Form 10-Q, and our other public filings with the U.S. Securities and Exchange Commission ("SEC"). However, these risks are not exhaustive and new risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this presentation or other filings with the SEC. Any forward-looking statements contained herein speak only as of the date of this presentation. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Nuvectis Pharma, Inc. 2 2
Page 3
NuvectisPharma, Inc. About Nuvectis 3 Shay Shemesh Chief Development & Operations Officer Jelmyto® (mitomycin) Management team with track record of success ▪ Global regulatory approvals (FDA, EMA and PMDA) in renal, anemia and oncology indications
Page 4
NuvectisPharma, Inc. Transformative Licensing Agreement with Haisco in June 2026 THE PARTNER Haisco Pharmaceutical Group (China) • ~50 marketed products and ~70 research programs • Licensing deals with Eli Lilly and AbbVie (2Q2026) • Discovered and advanced Alumis’ TYK2 inhibitor, envudeucitinib. Positive Phase 3 data in plaque psoriasis reported by Alumis in 1Q2026 POTENTIAL BEST -IN - CLASS, ADVANCED CLINICAL -STAGE PIPELINE Multibillion-dollar markets • Ciprocopan (NXP100): oral, once-daily Factor B inhibitor. • NXP200: oral, paradox-breaker BRAF inhibitor, in Phase 1b study in China FINANCIAL HIGHLIGHTS Completed $115M follow-on offering (July 2026) • Well positioned to reach key inflection points • Multiple near-term clinical and regulatory catalysts expected • Cash runway into 1H 2029 4 Well capitalized to execute a broad clinical plan
Page 5
NuvectisPharma, Inc. 5 Our Pipeline Precision medicine for the treatment of complement mediated diseases and cancer 5 Ciprocopan (NXP100): Factor B inhibitor for complement related diseases • Potential best in class, oral, once daily administration • First global approval in China for PNH in naïve patients and a marketing application under review in China for previously- treated PNH patients. • Late-stage studies ongoing in China for IgAN (Phase 3) and Lupus Nephritis (Phase 2) NXP900: SRC/YES1 kinase inhibitor for cancer • Enrolling Phase 1b combination study with osimertinib in EGFRmut+ NSCLC • Combination studies with lorlatinib in NSCLC and RAS inhibitors in pancreatic cancer pending. NXP200: Paradox Breaker BRAF Inhibitor for cancer • Paradox breaker, brain penetrant, oral BRAF inhibitor • Demonstrated durable single- agent responses in solid tumors and primary CNS cancers • Phase 1b expansion in solid tumors and primary brain cancer ongoing in China
Page 6
Ciprocopan (NXP100) Once Daily, Oral Factor B Inhibitor for the Treatment of Complement Related Diseases
Page 7
NuvectisPharma, Inc. Ciprocopan (NXP100): Convenient, Once-Daily Oral Factor B Inhibition Potential best-in-class complement Factor B inhibitor (CFBi) 1× Convenient, once-daily oral administration • Differentiated from oral, twice-daily Fabhalta (iptacopan), the only approved Factor B inhibitor • Ciprocopan efficacy demonstrated in treatment naïve and previously treated PNH patients • Safety profile similar to iptacopan Single oral dose provides 24-hour target inhibition Clinical and regulatory validation in PNH • China approval in treatment-naïve patients • Previously treated PNH indication approval pending in China Compelling efficacy supports best-in-class potential • Robust hemoglobin improvement demonstrated in PNH • Robust proteinuria reduction and eGFR increases in Phase 2 IgAN Broad development program targets additional large markets • Well positioned in PNH • Phase 3 study in IgAN and Phase 2 in lupus nephritis ongoing in China • Additional optionality in MG, dry AMD, C3G and other diseases 7
Page 8
NuvectisPharma, Inc. Ciprocopan/NXP100: Factor B is Becoming a Paramount Target in PNH 8a. Analyst report: https://www.thebusinessresearchcompany.com/report/paroxysmal-nocturnal-hemoglobinuria-pnh-global-market-repor 1ST GENERATION C5 Inhibitors Injectable anti-C5 antibodies Soliris · Ultomiris AstraZeneca / Alexion ~$6.4B combined revenue 2ND GENERATION Complement Factor B Inhibitors (CFBIs) Fabhalta (iptacopan) Novartis · Dosed twice daily orally The only approved Factor B inhibitor Strong ramp-up with Q2 2026 sales of $225M vs. Q1 $167M Next Generation CFBI Ciprocopan – Once-a-day, oral CFBI Positioned as potential best-in-class Market approval in China in treatment-naïve PNH, with approval pending in previously- treated PNH Pivotal, phase 3 study in IgAN and phase 2 in lupus nephritis ongoing in China PNH is currently a ~$4.7B market, projected to grow to ~$7.4B by 2030a ➢ Treatment is gradually shifting toward Factor B inhibition (oral, better efficacy) NXP100 and Fabhalta each demonstrated superiority over C5 inhibitors in head-to-head studies in PNH This sets the stage for CFBIs to become the dominant class in PNH
Page 9
NuvectisPharma, Inc. Ciprocopan’s First Global Approval (China): Treatment Naive PNH Demonstrated superiority vs Soliris (eculizumab, injectable C5 inhibitor class) 9 Primary endpoint - Proportion of participants achieving hemoglobin levels≥12 g/dL at least on three out of four measurements in the absence of RBC transfusions ➢ Average hemoglobin increase 5.0 g/dL in the ciprocopan arm vs 2.2 g/dL in the eculizumab arm * Ciprocopan = HSK39297/NXP100 Topline Phase 3 Results Ciprocopan* 200mg QD （N=37） Eculizumab （N=36） Proportion of patients achieving Hgb >12 g/dL 59.5% (43.2, 75.7) 8.3% (2.8,19.4) % of patients with ≥2 g/dL increase in Hgb from baseline % (95% CI) at week 24 91.9% (81.1, 100) 55.6% (38.9, 72.2) Treatment Period 24 weeks Randomized 1:1 Ciprocopan* 200mg QD Eculizumab
Page 10
NuvectisPharma, Inc. Ciprocopan’s 2nd Marketing Application in China: Previously-treated PNH - Patients with persistent anemia despite treatment with anti-C5 10 Primary endpoint - Proportion of participants achieving hemoglobin levels≥12 g/dL at least on three out of four measurements in the absence of RBC transfusions Primary Endpoint Ciprocopan* (N=36) Proportion of patients achieving Hgb >12 g/dL 19/36 (52.8%) (35.5, 69.6) Efficacy prospectively defined as having the lower bound of the 95% CI of the point estimate exceeding 20%. ➢ The study met primary endpoint with a 52.8% response rate and met all secondary endpoints Treatment Period 24 weeks Ciprocopan* 200 mg QD * Ciprocopan = HSK39297/NXP100
Page 11
NuvectisPharma, Inc. Ciprocopan (NXP100) Has Best In Class Potential in IgAN Phase 2 data efficacy positions ciprocopan potentially in line with APRIL/BAFF inhibitors (all injectables) 11 ➢ Urine Protein to Creatinine Ratio (UPCR) reduction: rapid onset of response and treatment effect increase over time; similar magnitude than BAFF/APRIL inhibitors approved or in development and numerically greater than Fabhalta (cross-trial comparison) ➢ Change in Estimated Glomerular Filtration Rate (eGFR): increase in eGFR indicates disease modifying potential ➢ Pivotal phase 3 study ongoing in China Parameter Week 4 Week 12 Week 24 Reduction in 24h-UPCR* relative to baseline vs. placebo -33% -45.3% (Primary Endpoint) -57.7% Change from baseline in estimated glomerular filtration rate (eGFR, mL/min/1.73m2) NXP100: +2.74 Placebo: -1.97 * Urine Protein to Creatinine Ratio
Page 12
NuvectisPharma, Inc. Competitive Landscape in PNH FDA Approved therapies – Factor B’s Expected to Become Leading Class 12 Condition Drug Name MoA Dosing Administration PNH Fabhalta Factor B Inhibitor Oral capsule twice daily Soliris C5 inhibitor IV infusion every 2 weeks Ultomiris C5 inhibitor IV infusion every 8 weeks Empaveli C3 Inhibitor Subcutaneous injection 2x weekly
Page 13
NuvectisPharma, Inc. Complement Factor B FDA Approvals and Ongoing Clinical Trials Indication Est. US addressable patient population Fabhalta approvals and ongoing clinical trials Ciprocopan (Status) APPROVALS PNH - Naive ~5,500 ● ● Treatment naïve (China) PNH - Experienced ● Approval pending (China) IgAN ~200,000 ● ● Phase 3 Ongoing (China) C3G ~9,000 ● — DEVELOPMENT LN ~100–200,000 ● ● Phase 2 Ongoing (China) IC-MPGN ~10,000 ● — aHUS ~2,000 ● — AAV ~140,000 ● — gMG ~70,000 ● — dAMD ~18MM ● ● IND accepted (China) ● Fabhalta (Iptacopan) Market ● Iptacopan (investigational) ● Ciprocopan/NXP100 NMPA approval ● Ciprocopan/NXP100 (investigational) Footnotes: US prevalence, approximate estimates based on epidemiology, claims, and registry estimates; dAMD represents early/intermediate AMD; Iptacopan = Fabhalta in investigational indications. IC-MPGN = Immune Complex-mediated membranoproliferative glomerulonephritis; AAV = ANCA-associated vasculitis; gMG – generalized myasthenia gravis; dAMD = dry age-related macular degenerationNuvectisPharma, Inc. 13
Page 14
NXP200 A Paradox-Breaker BRAF Inhibitor for the Treatment of Cancer
Page 15
NuvectisPharma, Inc. BRAF in Cancer 15 THE BRAF MUTATION • Class 1: mutations in codon 600 (most commonly V600E), active single monomers, RAS independent • Class 2: Non-V600 mutations or fusions, RAF dimerization dependent and RAS independent. • Class 3: low activity/kinase impaired mutations, RAF dimerization and RAS dependent FIRST GENERATION BRAF INHIBITORS • Can target only Class 1 mutations • Paradoxical activation leads to: o Short duration of response o Frequent skin side effects and skin tumors o Need to combine with MEK inhibitors Cancers with high prevalence of BRAF mutations Melanoma Colorectal NSCLC Papillary Thyroid CNS Cholangiocarcinoma WHY IT MATTERS FOR NXP200 • NXP200 is a paradox-breaking, BRAF inhibitor designed to block the pathway without triggering the paradoxical activation seen with first-generation BRAF inhibitors. • Can target all classes of BRAF mutations, brain-penetrant. • Demonstrated, durable, single- agent clinical activity in solid tumors and primary brain cancer
Page 16
NuvectisPharma, Inc. NXP200: A Large Next-Generation BRAF Opportunity 16 Oral, brain-penetrant, paradox-breaker BRAF inhibitor with potential best-in-class properties MARKET TODAY $5BN First-generation BRAF inhibitors MARKET POTENTIAL $12BN With next-generation paradox- breaker inhibitors* BENCHMARK DEAL $2.5BN Servier’s April 2026 acquisition of Day One Biopharmaceuticals, for BRAFi in pediatric glioma, just one subset of the CNS cancers NXP200 could address ➢ Development status: Phase 1b expansion ongoing in China in patients with BRAF-mutated solid tumors. ➢ Best-in-class potential: durable, single-agent responses in heavily pre-treated patients with primary CNS cancer and other solid tumors (CRC, NSCLC, melanoma, papillary thyroid, and others). * Analyst report: https://www.datainsightsmarket.com/reports/braf-inhibitors-301717
Page 17
NuvectisPharma, Inc. NXP200: Paradox Breaker BRAFi Clinical proof of concept: Single agent responses in heavily pre-treated patients 17 Preliminary Efficacy Data – Phase I dose escalation (all pts. Previously treated with recurrent metastatic disease) Cancer Type (all with V600X mutations) # of Patients Treated # of Confirmed Responses Adult Glioma 22 9 (41%) Colorectal Cancer 17 1 (6%) Melanoma 10 2 (20%) NSCLC 11 2 (18%) Craniopharyngioma Cholangiocarcinoma Papillary Thyroid Carcinoma 3 (1 in each disease) 3 (100%) Free Base (Old) Formulation Safety Summary • No DLTs, MTD not reached (doses: 200 – 3600 mg/day). • No AEs led to drug discontinuation or death. • Most TRAEs were grade 1 (76%), primarily asymptomatic laboratory. • No severe drug-related cutaneous toxicity reported. • Treatment with NXP200 resulted in ORR of 37% (7/19) including 1 CR in high-grade glioma (HGG) and 67% (2/3) in low-grade glioma (LGG). • The reported ORR of the dabrafenib plus trametinib combination is 33% in HGG and 54% in LGG (The Lancet Oncology, 2022). New salt form generated to enhance the PK properties of NXP200 – currently used in the Phase 1b clinical program in China
Page 18
NuvectisPharma, Inc. NXP200: New Salt Form Clinical proof of concept (pilot study): single agent responses in heavily pre-treated patients 18 Preliminary Single Agent Efficacy Data (all pts. previously treated with recurrent metastatic disease) Cancer Type (V600X mutations) # of Patients Treated Efficacy Colorectal Cancer 5 • 2 confirmed PRs (59% and 50.2% tumor reductions, >14 and 4 months and ongoing) • 2 SD (27% and 12% tumor reductions, including one BRAF resistant patient, >6 months, ongoing) Papillary Thyroid Carcinoma 1 • 1 PR (63.5% tumor reduction, >10 months) NSCLC 1 • Voluntary withdrawal, SD after 2 months New Salt form enhances NXP200 systemic exposure
Page 19
NXP900 A SRC/YES1 Kinase Inhibitor for the treatment of Cancer
Page 20
NuvectisPharma, Inc. NXP900 Phase 1b Ongoing Highly selective, unique mechanism of action: Complete shut-down of the YES1/SRC pathways by inhibiting the catalytic and scaffolding properties 20 #1: NSCLC: osimertinib combination - EGFR mutated, previous response to osimertinib - ongoing #2: NSCLC: lorlatinib combination - ALK fusion, previous response to lorlatinib, commencement pending #3: Pancreatic Cancer: KRAS inhibitor combination - investigator initiated study planned
Page 21
NuvectisPharma, Inc. NXP900 Combination With RAS Inhibitors SRC activation is involved in multiple pathways leading to acquired resistance to Ras inhibition** 21 Cancer Res (2026) 86 (7_Supplement): 6495. ** AACR 2026 1 SRC, YES1 and YAP1 activation have been validated preclinically as drivers of resistance to RAS inhibitors. 2 NXP900 inhibits at low nanomolar concentrations SRC overactivation in sotorasib-resistant NSCLC cells and inhibits YAP1 nuclear localization (a marker of acquired resistance). 3 Low nanomolar concentrations of NXP900 result in potent synergy in cell proliferation assays in combination with sotorasib in sensitive and resistant NSCLC cells.
Page 22
Milestones and News Flow
Page 23
NuvectisPharma, Inc. Expected Near-Term News Flow & Catalysts 23 Program Potential Catalyst Estimated Timeline Complement Approval (China) — treatment-naïve PNH ✓ July 2026 Approval (China) — previously-treated PNH Q4 2026 PNH Phase 3 data (China) presentations at ASH Dec 2026 US IND submission H2 2026 IgAN Pivotal Phase 3 Topline (China) H1 2027 Phase 2 LN data update (China) H2 2026 Fabhalta data updates across multiple indications Starting H2 2026 Oncology NXP200 Phase 1b expansion update (China) Q4 2026 NXP200 US IND submission Q4 2026 NXP900 Phase 1b combination data update Q4 2026
Page 24
Nuvectis Pharma, Inc. (NASDAQ: NVCT) Precision Medicine for the Treatment of Complement Related Diseases and Cancer (NASDAQ: NVCT) August 2026